Quarterly report · Q2
4548.TEDINET S100SALX
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥18.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥33.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥17.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥1.5bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥2.6bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥2.3bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.6bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.3bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.6bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥3.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥79.6bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥75.6bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥77.8bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥8.1bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥8.4bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥71.5bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥67.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥69.8bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥18.0bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥23.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥21.0bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥25.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥24.4bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥23.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥490m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥268m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥3.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥1.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥731m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.9bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥38.54 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥3.93 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥40.49 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥56.32 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥29.72 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 89.9% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.6% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E00970-000LALreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.0bn |
| jpcrp040300-q2r_E00970-000LALreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥5.0bn |
| jpcrp040300-q2r_E00970-000LALreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥420m |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥13.1bn |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥13.1bn |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.1bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥18.1bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥18.1bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.5bn |
| jpcrp040300-q2r_E00970-000LALreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥5.6bn |
| jpcrp040300-q2r_E00970-000LALreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥5.6bn |
| jpcrp040300-q2r_E00970-000LALreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥11.7bn |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥11.7bn |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.2bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥17.3bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥17.3bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥2.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 525
| Item | Context | Value | Unit |
|---|---|---|---|
| Business structure improvement expenses noe | Prior1YTDDuration | - | JPY |
| Business structure improvement expenses noe | CurrentYTDDuration | 29000000 | JPY |
| Other noe | Prior1YTDDuration | 0 | JPY |
| Other noe | CurrentYTDDuration | 1000000 | JPY |
| Non operating expenses | Prior1YTDDuration | 5000000 | JPY |
| Non operating expenses | CurrentYTDDuration | 35000000 | JPY |
| Ordinary income | Prior1YTDDuration | 3600000000 | JPY |
| Ordinary income | CurrentYTDDuration | 2327000000 | JPY |
| Income before income taxes | Prior1YTDDuration | 3600000000 | JPY |
| Income before income taxes | CurrentYTDDuration | 2327000000 | JPY |
| Income taxes current | Prior1YTDDuration | 393000000 | JPY |
| Income taxes current | CurrentYTDDuration | 249000000 | JPY |
| Income taxes deferred | Prior1YTDDuration | 65000000 | JPY |
| Income taxes deferred | CurrentYTDDuration | -24000000 | JPY |
| Income taxes | Prior1YTDDuration | 458000000 | JPY |
| Income taxes | CurrentYTDDuration | 224000000 | JPY |
| Profit loss | Prior1YTDDuration | 3141000000 | JPY |
| Profit loss | CurrentYTDDuration | 2102000000 | JPY |
| Profit loss attributable to owners of parent | Prior1YTDDuration | 3141000000 | JPY |
| Profit loss attributable to owners of parent | CurrentYTDDuration | 2102000000 | JPY |
| Profit loss | Prior1YTDDuration | 3141000000 | JPY |
| Profit loss | CurrentYTDDuration | 2102000000 | JPY |
| Valuation difference on available for sale securities net of tax oci | Prior1YTDDuration | -435000000 | JPY |
| Valuation difference on available for sale securities net of tax oci | CurrentYTDDuration | 1346000000 | JPY |
| Deferred gains or losses on hedges net of tax oci | Prior1YTDDuration | -63000000 | JPY |
| Deferred gains or losses on hedges net of tax oci | CurrentYTDDuration | 14000000 | JPY |
| Foreign currency translation adjustment net of tax oci | Prior1YTDDuration | 2444000000 | JPY |
| Foreign currency translation adjustment net of tax oci | CurrentYTDDuration | 1605000000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | Prior1YTDDuration | 85000000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | CurrentYTDDuration | -46000000 | JPY |
| Other comprehensive income | Prior1YTDDuration | 2031000000 | JPY |
| Other comprehensive income | CurrentYTDDuration | 2919000000 | JPY |
| Comprehensive income | Prior1YTDDuration | 5173000000 | JPY |
| Comprehensive income | CurrentYTDDuration | 5021000000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 5173000000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 5021000000 | JPY |
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | - | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | - | JPY |
| Income before income taxes | Prior1YTDDuration | 3600000000 | JPY |
| Income before income taxes | CurrentYTDDuration | 2327000000 | JPY |
| Depreciation and amortization ope cf | Prior1YTDDuration | 526000000 | JPY |
| Depreciation and amortization ope cf | CurrentYTDDuration | 684000000 | JPY |
| Amortization of goodwill ope cf | Prior1YTDDuration | 84000000 | JPY |
| Amortization of goodwill ope cf | CurrentYTDDuration | 87000000 | JPY |
| Increase decrease in provision for bonuses ope cf | Prior1YTDDuration | -44000000 | JPY |
| Increase decrease in provision for bonuses ope cf | CurrentYTDDuration | 37000000 | JPY |
| Increase decrease in net defined benefit asset or liability ope cf | Prior1YTDDuration | -26000000 | JPY |
| Increase decrease in net defined benefit asset or liability ope cf | CurrentYTDDuration | -33000000 | JPY |
| Interest and dividends income ope cf | Prior1YTDDuration | -192000000 | JPY |
| Interest and dividends income ope cf | CurrentYTDDuration | -267000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |